GRI · GRI Bio, Inc.
$1.48
-0.03 (-1.99%)
At close · Jul 22
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Therefore, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$2.62M
Shares
1.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.48
Open$1.51
Day$1.46–1.57
52W$1.42–80.36
Avg vol 30d89K
Short int115K · 6.5% float · 1.0d
Short vol10%
Last earningsFeb 4, 2026
DataFeb 2021–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−90%
below
Price vs 50-day avg
−25%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−64%
trailing
YTD return
−79%
this year
Relative strength
−71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
+500% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.49% of float · ▼ -14.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — 13F breadth
Squeeze score
46
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+92%
Y/Y
Free cash flow
$-10.2M
Valuation
P/E 0
below peers
Balance sheet
$8.2M
net cash
Quant / Vol
risk profile
Volatility
125%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−90%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
+500% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.49% of float · ▼ -14.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
6 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $1
Now $1 · 0%
52-wk high $80
vs 200-day avg -90%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRI
this stock
GRI Bio, Inc.
|
$2.62M | -78.6% | -100.0% | 0.0 | 6.5% |
|
ONC
BeOne Medicines Ltd.
|
$462.38B | +5.3% | +22179.2% | 941.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.94B | +4.2% | +46.2% | 28.1 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.27B | -15.5% | +20.8% | 15.9 | 3.3% |
|
ARGX
Argenx SE
|
$53.28B | +1.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRI | -8.6% | -20.4% | -64.0% | -16.4% | -78.6% |
| SPY | -1.0% | +1.9% | +7.5% | +0.1% | +9.6% |
| vs SPY | -7.7% | -22.3% | -71.5% | -16.5% | -88.2% |